MX389581B - Compuestos que contienen nitrogeno sustituido. - Google Patents

Compuestos que contienen nitrogeno sustituido.

Info

Publication number
MX389581B
MX389581B MX2019014411A MX2019014411A MX389581B MX 389581 B MX389581 B MX 389581B MX 2019014411 A MX2019014411 A MX 2019014411A MX 2019014411 A MX2019014411 A MX 2019014411A MX 389581 B MX389581 B MX 389581B
Authority
MX
Mexico
Prior art keywords
sup
compounds
compounds containing
substituted nitrogen
containing substituted
Prior art date
Application number
MX2019014411A
Other languages
English (en)
Other versions
MX2019014411A (es
Inventor
Eldon Scott Priestley
Jeremy Richter
Manoranjan Panda
Navnath Dnyanoba Yadav
Prashantha Gunaga
Rajeev S Bhide
Rajesh Onkardas Bora
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2019014411A publication Critical patent/MX2019014411A/es
Publication of MX389581B publication Critical patent/MX389581B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula (I) (ver Fórmula) o una sal del mismo, en donde R1 es: (ver Fórmula) o (ver Fórmula); cada W es, independientemente, NR1b u O; Z es un enlace o CHR1d; y R1, R2, Rd, R3a, R3b, L1, B, V, Y y n se definen como en la presente. También se describen métodos para usar tales compuestos como inhibidores de ROMK, y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles para tratar enfermedades cardiovasculares.
MX2019014411A 2017-06-01 2018-05-31 Compuestos que contienen nitrogeno sustituido. MX389581B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201711019293 2017-06-01
IN201811004486 2018-02-06
PCT/US2018/035270 WO2018222795A1 (en) 2017-06-01 2018-05-31 Substituted nitrogen containing compounds

Publications (2)

Publication Number Publication Date
MX2019014411A MX2019014411A (es) 2020-02-05
MX389581B true MX389581B (es) 2025-03-20

Family

ID=62685190

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014411A MX389581B (es) 2017-06-01 2018-05-31 Compuestos que contienen nitrogeno sustituido.

Country Status (27)

Country Link
US (6) US10501449B2 (es)
EP (2) EP3929194B1 (es)
JP (2) JP7084946B2 (es)
KR (1) KR102655318B1 (es)
CN (1) CN110678463B (es)
AU (1) AU2018275552B2 (es)
CA (1) CA3065309A1 (es)
CL (1) CL2019003486A1 (es)
CO (1) CO2019013589A2 (es)
CY (1) CY1124479T1 (es)
DK (1) DK3630752T3 (es)
ES (2) ES2981919T3 (es)
HR (1) HRP20211262T1 (es)
HU (1) HUE056142T2 (es)
IL (1) IL271036B2 (es)
LT (1) LT3630752T (es)
MX (1) MX389581B (es)
MY (1) MY201325A (es)
PE (1) PE20200386A1 (es)
PL (1) PL3630752T3 (es)
PT (1) PT3630752T (es)
RS (1) RS62277B1 (es)
SI (1) SI3630752T1 (es)
SM (1) SMT202100512T1 (es)
TW (1) TWI791527B (es)
WO (1) WO2018222795A1 (es)
ZA (1) ZA201908488B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2902527T3 (es) * 2016-11-03 2022-03-28 Bristol Myers Squibb Co Derivados biciclo heterocíclicos sustituidos, útiles como inhibidores del canal ROMK
MY201325A (en) * 2017-06-01 2024-02-16 Bristol Myers Squibb Co Substituted nitrogen containing compounds
BR112022011917A2 (pt) 2019-12-20 2022-09-06 Tenaya Therapeutics Inc Fluoroalquil-oxadiazois e seus usos
KR20230007453A (ko) * 2020-05-06 2023-01-12 바이오하벤 테라퓨틱스 리미티드 베르디퍼스타트의 제조 과정
MX2023012875A (es) 2021-05-04 2024-01-12 Tenaya Therapeutics Inc Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
CN114957222B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 化合物及其制备方法和用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078716A1 (en) 1999-06-24 2000-12-28 Toray Industries, Inc. α1B-ADRENERGIC RECEPTOR ANTAGONISTS
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
KR100882179B1 (ko) 2001-06-20 2009-02-06 깃세이 야쿠힌 고교 가부시키가이샤 함질소 복소환 유도체, 그것을 함유하는 의약 조성물, 그의약 용도 및 그 제조 중간체
AU2003223467B2 (en) 2002-04-08 2007-10-04 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2481229C (en) 2002-04-08 2010-09-21 Merck & Co., Inc. Substituted pyrazine inhibitors of akt
KR20070036149A (ko) 2004-07-16 2007-04-02 얀센 파마슈티카 엔.브이. 이량체 피페리딘 유도체
MX2007006109A (es) 2004-12-01 2007-10-04 Devgen Nv Derivados de tiazol sustituidos en 5-carboxamido que interactuan con canales de iones, en particular con canales ionicos de la familia de kv.
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
CN102014927A (zh) 2008-03-06 2011-04-13 安纳考尔医药公司 作为抗炎药的含硼的小分子
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
BRPI1012852A2 (pt) 2009-05-15 2018-06-19 Novartis Ag derivados de benzoxazolona como inibidores da sintase de aldoesterona
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
EP2536690B1 (en) 2010-02-19 2018-08-08 Arizona Board Of Regents Multifunctional radical quenchers and their use
CA2812088A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR20140052034A (ko) 2011-08-19 2014-05-02 머크 샤프 앤드 돔 코포레이션 신장 외수질 칼륨 채널의 억제제
EP2755656B1 (en) 2011-09-16 2016-09-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062892A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9206199B2 (en) * 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9777002B2 (en) 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014150132A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
LT3055302T (lt) 2013-10-11 2019-03-12 F. Hoffmann-La Roche Ag Pakeistieji heterocikliniai sulfonamidiniai junginiai, tinkami naudoti kaip trpa1 moduliatoriai
WO2015065866A1 (en) * 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3083573B1 (en) 2013-12-18 2024-08-07 Merck Sharp & Dohme LLC Inhibitors of the renal outer medullary potassium channel
WO2015090579A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
WO2015096035A1 (en) 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016008064A1 (en) 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
KR20170021358A (ko) 2014-07-14 2017-02-27 머크 샤프 앤드 돔 코포레이션 신장 외수질성 칼륨 채널의 억제제
WO2016060941A1 (en) 2014-10-14 2016-04-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
EP3212617A1 (en) 2014-10-31 2017-09-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6736816B2 (ja) 2014-12-08 2020-08-05 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピリジンカルボキサミド誘導体、それらの製造方法およびそれらの医薬用途
CN105693706B (zh) 2014-12-10 2019-11-22 江苏恒瑞医药股份有限公司 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用
EP3250204B1 (en) 2015-01-29 2019-10-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2017001991A1 (en) 2015-06-29 2017-01-05 Crystalmorphix Technologies Pvt. Ltd Cocrystals of trigonelline
MX381425B (es) 2016-04-20 2025-03-12 Bristol Myers Squibb Co Compuestos heterociclicos biciclicos sustituidos.
ES2902527T3 (es) 2016-11-03 2022-03-28 Bristol Myers Squibb Co Derivados biciclo heterocíclicos sustituidos, útiles como inhibidores del canal ROMK
MY201325A (en) * 2017-06-01 2024-02-16 Bristol Myers Squibb Co Substituted nitrogen containing compounds

Also Published As

Publication number Publication date
EP3929194B1 (en) 2024-04-17
TW201902888A (zh) 2019-01-16
US20200339550A1 (en) 2020-10-29
TWI791527B (zh) 2023-02-11
CN110678463A (zh) 2020-01-10
KR102655318B1 (ko) 2024-04-04
LT3630752T (lt) 2021-08-25
MY201325A (en) 2024-02-16
CO2019013589A2 (es) 2020-04-01
ZA201908488B (en) 2023-10-25
US10501449B2 (en) 2019-12-10
AU2018275552B2 (en) 2022-01-20
HUE056142T2 (hu) 2022-01-28
IL271036B (en) 2022-11-01
JP7406592B2 (ja) 2023-12-27
HRP20211262T1 (hr) 2021-11-12
USRE49700E1 (en) 2023-10-17
ES2981919T3 (es) 2024-10-11
US20240327390A1 (en) 2024-10-03
PL3630752T3 (pl) 2021-11-02
IL271036B2 (en) 2023-03-01
MX2019014411A (es) 2020-02-05
SMT202100512T1 (it) 2021-11-12
PT3630752T (pt) 2021-08-10
JP2020522490A (ja) 2020-07-30
US20180346453A1 (en) 2018-12-06
PE20200386A1 (es) 2020-02-24
US20230124468A1 (en) 2023-04-20
EP3929194A1 (en) 2021-12-29
JP2022130404A (ja) 2022-09-06
DK3630752T3 (da) 2021-08-09
BR112019024950A2 (pt) 2020-06-23
EP3630752A1 (en) 2020-04-08
CN110678463B (zh) 2023-06-06
IL271036A (en) 2020-01-30
CL2019003486A1 (es) 2020-05-15
AU2018275552A1 (en) 2020-01-23
US20200109135A1 (en) 2020-04-09
CY1124479T1 (el) 2022-07-22
ES2885243T3 (es) 2021-12-13
KR20200011986A (ko) 2020-02-04
WO2018222795A1 (en) 2018-12-06
CA3065309A1 (en) 2018-12-06
EP3630752B1 (en) 2021-06-30
RS62277B1 (sr) 2021-09-30
JP7084946B2 (ja) 2022-06-15
SI3630752T1 (sl) 2021-10-29

Similar Documents

Publication Publication Date Title
MX389581B (es) Compuestos que contienen nitrogeno sustituido.
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
ECSP22012347A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
PH12022550029A1 (en) Deuterated mk2 pathway inhibitors and methods of using the same
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA202090256A1 (ru) 5-членные и бициклические гетероциклические амиды в качестве ингибиторов rock
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
EA201991095A1 (ru) Замещенные азотсодержащие соединения
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX2021012749A (es) Inhibidor selectivo de la jak1 cinasa.
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201791671A1 (ru) 4-замещенные соединения бензоксаборола и их применение
SA521422728B1 (ar) مثبطات فوسفوينوسيتيد 3- كيناز الموضعية
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы